Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief...
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
November 13, 2023 18:50 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and...
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023 08:30 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for...
Vaxxinity to Present at Upcoming Investor Conferences in September
August 29, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief...
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
August 10, 2023 08:00 ET
|
Vaxxinity, Inc.
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the...
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for...
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
July 27, 2023 16:30 ET
|
Vaxxinity, Inc.
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc....
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
July 17, 2023 08:00 ET
|
Vaxxinity, Inc.
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
June 22, 2023 08:00 ET
|
Vaxxinity, Inc.
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies,...
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...